Search bioRxiv⌕ Search

bioRxiv · 10.1101/2021.04.02.438193

Benchmarking scRNA-seq imputation tools with respect to network inference highlights deficits in performance at high levels of sparsity

Abstract

Gene correlation network inference from single-cell transcriptomics data potentially allows to gain unprecendented insights into cell type-specific regulatory programs. ScRNA-seq data is severely affected by dropout, which significantly hampers and restrains current downstream analysis. Although newly developed tools are capable to deal with sparse data, no appropriate single-cell network inference workflow has been established. A potential way to end this deadlock is the application of data imputation methods, which already proofed to be useful in specific contexts of single-cell data analysis, e.g., recovering cell clusters. In order to infer cell-type specific networks, two prerequisites must be met: the identification of cluster-specific cell-types and the network inference itself. Here, we propose a benchmarking framework to investigate both objections. By using suitable reference data with inherent correlation structure, six representative imputation tools and appropriate evaluation measures, we were able to systematically infer the impact of data imputation on network inference. Major network structures were found to be preserved in low dropout data sets. For moderately sparse data sets, DCA was able to recover gene correlation structures, although systematically introducing higher correlation values. No imputation tool was able to recover true signals from high dropout data. However, by using an additional biological data set we could show that cell-cell correlation by means of specific marker gene expression was not compromised through data imputation. Our analysis showed that network inference is feasible for low and moderately sparse data sets by using the unimputed and DCA-prepared data, respectively. High sparsity data, on the other side, still pose a major problem since current imputation techniques are not able to facilitate network inference. The annotation of cluster-specific cell-types as a prerequisite is not hampered by data imputation but their power to restore the deeply hidden correlation structures is still not sufficient enough.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Steinheuer, L. M., Canzler, S., Hackermüller, J.. 2021-04-02. Benchmarking scRNA-seq imputation tools with respect to network inference highlights deficits in performance at high levels of sparsity. https://doi.org/10.1101/2021.04.02.438193

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Accelerating discovery and integration from RNA to Protein with R2T2P

Integrating transcriptomics and proteomics data remains an unmet challenge in the post-genomics era, discouraging researchers from pursuing integrative approaches to molecular biology research. Leveraging the power of translation profiling, we present RNA to Translation to Protein (R2T2P), a computational platform integrating genome-guided transcriptome assembly with identification of translation and proteins, including a tailored differential analysis framework and support for multiple reference transcriptomes. We applied R2T2P to investigate a cellular model of facioscapulohumeral muscular dystrophy (FSHD), where ectopic expression of the DUX4 retrogene in skeletal muscle triggers significant alterations in transcription and RNA metabolism. We uncovered hundreds of uncharacterized, highly overexpressed RNAs, including antisense and alternative transcripts, and quantified their contribution to translatome and proteome. Re-analysis of expression datasets from patient-derived myotubes and muscle biopsies validated this alternative transcriptome in FSHD patients, adding a reservoir of bona-fide novel molecular actors in a rare disease. Available at https://github.com/nfdata-omics/R2T2P/, R2T2P is a flexible and powerful workflow in modern integrative biology.

bioinformatics↗

MorphoANOVA: Dissecting Histology-Gene Expression Relationships in Spatial Transcriptomics

Spatial transcriptomics (ST) measures the expression of hundreds to thousands of genes within tissue architecture, often accompanied by histology images. However, it remains challenging to systematically characterize which genes exhibit associations with tissue morphology, whether these associations vary spatially, and which genes show additional spatial expression patterns beyond those captured by morphology. Here we introduce MorphoANOVA, a gene-wise statistical framework for characterizing morphology--expression relationships across genes measured by ST. Using nested spatially varying coefficient models and sequential ANOVA, MorphoANOVA assesses slide-wide associations with an H\&E-derived morphology feature, location-specific changes in these associations, and additional spatial variation after accounting for the selected feature. The resulting statistics enable gene prioritization and pathway enrichment analysis, while spatial component maps support the interpretation of individual genes. Simulations demonstrate MorphoANOVA's ability to distinguish the modeled components and recover their spatial patterns. Applications to human cortex and breast cancer identify biological programs associated with different morphology--expression patterns and reveal distinct relationships with cell composition. Across three HER2-positive breast cancer patients, invasive-cancer marker genes consistently exhibit stronger evidence of location-specific morphology associations. MorphoANOVA thus provides a framework for systematically interpreting spatial gene-expression patterns in relation to tissue morphology.

bioinformatics↗

Evaluation effects can rival reported concordance gains in cross-cancer survival prediction

Studies of cross-cancer learning for survival prediction from tumour omics have reported concordance gains of 0.020 and 0.045, but how such gains compare with evaluation effects remains unclear. We examined these effects across 13 TCGA cancers (5,761 patients, 1,526 disease-specific deaths), using five repeats of five-fold cross-validation and paired bootstrap intervals. When model selection did not use test data, our borrowing model gained 0.009 (95% interval 0.001 to 0.016) over its target-fitted reference when cancers received equal weight (post hoc). Random-effects pooling gave a gain of 0.002 (-0.002 to 0.006), with most weight assigned to cancers where the model made little use of the pretrained score. Choosing the fusion weight on test splits raised the apparent equal-weight gain to 0.017. We reimplemented a published method, VAECox, which showed no pretraining gain over random initialisation at the last or validation-selected training step. Choosing each network's best test step, as the published code does, raised concordance by 0.03 to 0.05 across the 13-cancer and ten-cancer overall-survival settings, but barely changed the difference between networks. In a constructed post hoc experiment, choosing the best test step only for the pretrained network changed the equal-weight mean difference from -0.004 to +0.045 (+0.035 to +0.054). Across seven multi-omics comparisons, estimates from single five-fold runs differed from their cancer's five-run mean by at least 0.02 in 11% to 42% of runs. Concordance was about 0.02 lower at held-out tissue source sites. Interpreting a reported gain therefore requires each model's selection rule, variation across repeated partitions, the weighting of cancers and the evaluation population.

bioinformatics↗